Literature DB >> 7028800

Cholinergic challenges in affective illness: behavioral and neuroendocrine correlates.

S C Risch, N H Kalin, D S Janowsky.   

Abstract

The cholinergic-adrenergic balance hypothesis of affective disorders suggests that, in the areas of the brain that regulate mood, depression may represent a relative predominance of central cholinergic tone over adrenergic tone and that mania may represent the converse. Currently, converging lines of investigation from a number of independent groups suggest that affective disorder patients may have a central cholinergic receptor hypersensitivity that induces a vulnerability to affective and neuroendocrine disturbances. This article reviews the evidence for cholinergic mechanisms in the regulation of affective state and describes current research strategies using centrally active cholinomimetic agents to explore disturbances in affective disorder subjects.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7028800     DOI: 10.1097/00004714-198107000-00003

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  19 in total

1.  The prominent role of stimulus processing: cholinergic function and dysfunction in cognition.

Authors:  Maura L Furey
Journal:  Curr Opin Neurol       Date:  2011-08       Impact factor: 5.710

2.  Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.

Authors:  Maura L Furey; Wayne C Drevets
Journal:  Arch Gen Psychiatry       Date:  2006-10

3.  Central muscarinic effects of physostigmine on mood, cardiovascular function, pituitary and adrenal neuroendocrine release.

Authors:  D S Janowsky; S C Risch; B Kennedy; M Ziegler; L Huey
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 4.  Genetic and pharmacological models of cholinergic supersensitivity and affective disorders.

Authors:  D H Overstreet; R W Russell; A D Crocker; J C Gillin; D S Janowsky
Journal:  Experientia       Date:  1988-06-15

5.  Central cholinergic stimulation causes adrenal epinephrine release.

Authors:  B Kennedy; D S Janowsky; S C Risch; M G Ziegler
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

6.  Scopolamine detoxification technique for heroin dependence: a randomized trial.

Authors:  Sheng Liu; Longhui Li; Wenwen Shen; Xueyong Shen; Guodong Yang; Wenhua Zhou
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

Review 7.  Future antidepressants: what is in the pipeline and what is missing?

Authors:  Fokko J Bosker; Ben H C Westerink; Thomas I F H Cremers; Marjolein Gerrits; Marieke G C van der Hart; Sjoukje D Kuipers; Gieta van der Pompe; Gert J ter Horst; Johan A den Boer; Jakob Korf
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder.

Authors:  D M Cannon; J K Klaver; S K Gandhi; G Solorio; S A Peck; K Erickson; N Akula; J Savitz; W C Eckelman; M L Furey; B J Sahakian; F J McMahon; W C Drevets
Journal:  Mol Psychiatry       Date:  2010-03-30       Impact factor: 15.992

9.  Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial.

Authors:  Wayne C Drevets; Maura L Furey
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

Review 10.  Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review.

Authors:  Wayne C Drevets; Carlos A Zarate; Maura L Furey
Journal:  Biol Psychiatry       Date:  2012-11-28       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.